Medprin disclosed the progress of the equity transaction for acquiring Yijie Medical, with uncertainties still remaining

Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. announced the progress of the issuance of shares and cash payment for asset acquisition and the fundraising of supporting funds, as well as related party transactions. The company intends to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd., which is expected not to constitute a major asset reorganization but to constitute a related party transaction. The planning of this transaction began on May 22, 2025, going through stages of suspension and resumption of trading. As of the announcement date on September 30, the company is cooperating with intermediaries to conduct due diligence and other work, which has not yet been completed. This transaction still requires approval from the board of directors and the shareholders' meeting, as well as review by the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, which carries uncertainty. The company will disclose progress in a timely manner